Medico Reach

DECEMBER 2, 2022

billion , and by 2027, it is expected to reach around an exciting amount of 115.1 from 2022 to 2027. Some clinical trials offered by PPD include: Early Development Consulting and Product Development PPD Biotech PPD FSP The site and patient-centered Solutions Clinical Development. billion with a CAGR of 11.0% Medpace Holdings.

Consulting 98

Consulting Specialization Medicine Medical 98

pharmaphorum

OCTOBER 1, 2022

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US. Gilenya made revenues of $2.8 Sales in the first half of this year fell 19% to $1.16

Competition 52

Competition Pharma Marketing Sales 52

pharmaphorum

JULY 18, 2022

. “The acceptance of the filing of proposed biosimilar natalizumab by the European regulatory authorities means we are a critical step closer to getting this important medicine to the patients who need it the most,” said Polpharma Biologics’ chief executive Michael Soldan in a statement.

Competition 52

Competition Marketing Sales Medicine 52

LEVO Health

JULY 15, 2024

billion by 2027. To stand out in this competitive landscape, businesses must focus on patient engagement, comprehensive service offerings, strong marketing and branding, and strategic partnerships with top-tier telehealth service providers like WellSync and medical marketing experts like Levo Health.

Marketing 52

Marketing Side effects Education Medical 52

pharmaphorum

JANUARY 16, 2023

Even where there has been innovation, for example in cholesterol lowering with PCSK-9s and the siRNA treatment Leqvio, the vast majority of patients are on generic versions of medicines launched in the 1990s, and innovative medicines have not transformed the treatment paradigm. Innovation will power the market. About the author.

FDA 98

FDA Healthcare Healthcare Medicine 98

Clarivate

AUGUST 27, 2024

With the global atrial fibrillation market at $6 billion today, that rate of growth would push it to $12 billion by mid-2027, if not sooner, with PFA accounting for about 70% of the market. In addition, the improved safety profile of PFA is making the cost-benefit of ablation an easier calculation for many patients.

Marketing 52

Marketing Competition FDA Electronics 52

pharmaphorum

JANUARY 27, 2023

An additional note of optimism is that UK biotechs achieved pivotal milestones in their development, with Verona Pharma reporting a successful phase 3 trial for Ensifentrine, the first novel compound in over 10 years to address the ongoing needs of more than 380 million patients worldwide suffering from Chronic Obstructive Pulmonary Disease (COPD).

Pharma 52

Pharma Manufacturing Medicine Biopharma 52

Clarivate

APRIL 24, 2023

Health systems will buy or establish an insurance plan to serve as an extension of their continuum of care, a means of directing referral streams to increase revenue and securing control over clinical and formulary decisions for patients. In January 2023, VillageMD acquired Summit Health for $8.9

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Marketing 52

Marketing Physicians Leads Sales 52

Medico Reach

FEBRUARY 8, 2023

Big data can help clinical trial design, allowing researchers to leverage genetic makeup, historical patient data, past trial results, demographics, and more to find the right participants. billion by 2027. R&D in Personalized Medicine Customized or precision medicine offers tremendous prospects for treating many illnesses.

Pharma 52

Pharma Medicine Marketing Prospecting 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

European Pharmaceutical Review

FEBRUARY 7, 2023

In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR. However, a delicate balance will need to be struck between the need for affordable and accessible medicinal products and the desire to foster innovation and competitiveness in the EU.

Medical 117

Medical Government Marketing Medicine 117

Evolve Your Success

OCTOBER 31, 2023

Neuromodulation isn’t just about stimulating nerves; it’s about awakening hope and transforming lives—one patient at a time. In this episode, Blake Williams takes us on a wild journey through his career as a Field Clinical Engineer (FCE), shedding light on the incredible impact of neuromodulation on the lives of patients.

Engineering 52

Engineering Sales Medical sales Medical 52

Pharmaceutical Technology

NOVEMBER 30, 2022

Previously, the standard of care for obesity consisted of holistic changes to diet, exercise, and bariatric surgery for eligible patients. However, despite the effectiveness of bariatric surgery, many obese patients are reluctant to undergo surgical procedures, opening the opportunity for a pharmaceutical approach.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

Previously, the standard of care for obesity consisted of holistic changes to diet, exercise, and bariatric surgery for eligible patients. However, despite the effectiveness of bariatric surgery, many obese patients are reluctant to undergo surgical procedures, opening the opportunity for a pharmaceutical approach.

Medical 98

Medical Manufacturing Insurance Side effects 98

Clarivate

AUGUST 20, 2024

In 2025, CMS will select another 15 Part D drugs for negotiations that will take effect in 2027. 1, 2024, following an IRA provision capping patients’ out-of-pocket costs at $35 per month. In highly competitive categories like diabetes, net price could be half of the list price.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Pharmaceutical Technology

FEBRUARY 6, 2023

After 12 weeks, the study met its primary endpoint related to the “number of participants with treatment-related adverse events and laboratory abnormalities” for patients in the 320mg group, as there were no study-related adverse events. The company plans to release the final data in Q2 2023.

Marketing 59

Marketing Pharmaceutical FDA Prospecting 59